Concepedia

Author

Julia Hocke

Boehringer Ingelheim (Germany)

Also Known As

Hocke, J., J. Hocke, Julia Hocke

22

Publications

312

Citations

8

H-Index

25

Concepts

All Affiliations

Boehringer Ingelheim (Germany)Boehringer Ingelheim (Netherlands)National Cheng Kung University HospitalCRUK Lung Cancer Centre of ExcellenceUniversity College London
JH

About

Julia Hocke is an author at Boehringer Ingelheim (Germany) specializing in medicine, pharmacotherapy, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

140

2

Health Sciences

2

2

26

3

Hepatology

2

2

26

4

Pathology

2

2

26

5

Epidemiology

1

1

13

Julia Hocke

×

8

Publications

268

Citations

8

H-Index

YearCitations

<scp>mRECIST</scp> to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase <scp>II</scp> trials comparing nintedanib vs sorafenib

Tim Meyer, Daniel H. Palmer, Ann‐Lii Cheng,

Liver International

2017

71

Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir

Sven Wind, Arvid Jungnik, Tobias Brand,

Clinical Drug Investigation

2014

60

A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma

Daniel H. Palmer, Markus Peck‐Radosavljevic, Paul J. Ross,

British Journal of Cancer

2018

31

Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment

Eric Van Cutsem, Takayuki Yoshino, Julia Hocke,

Clinical Colorectal Cancer

2015

27

Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel

Martin Reck, Anders Mellemgaard, Joachim von Pawel,

Lung Cancer

2015

27

A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma

Chia-Jui Yen, Tae‐You Kim, Yin‐Hsun Feng,

Liver Cancer

2018

26

Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC).

Daniel H. Palmer, Yuk Ting, Markus Peck‐Radosavljevic,

Journal of Clinical Oncology

2015

13

Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomized phase II trial.

Ann‐Lii Cheng, Chia‐Jui Yen, Tae‐You Kim,

Journal of Clinical Oncology

2015

13

Page 1